Multicenter phase II study of lurbinectedin in BRCAMutated and unselected metastatic advanced breast cancer and biomarker assessment substudy.
Journal of Clinical Oncology.
Times cited: 5
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.
Annals of Oncology.
Times cited: 75
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
JAMA - Journal of the American Medical Association.
Times cited: 323